Her-2/neu positive for the treatment of locally advanced breast cancer chemotherapy leading prescription alternative

The study research team in the United States in April 2007 in the "Journal of Clinical Oncology" published. 
Their section 2B, and 3 and of Her-2/neu positive locally advanced breast cancer, given every two weeks for a course of Taxol in Europe, to eliminate cancer-ping (docetaxel 60 mg/m2, vinorelbine 45 mg/m2) plus He's cancer-ping, a total of 3 months. Before surgery, a pre-assessment of the clinical effectiveness of chemotherapy prescription. 
The results showed that this prescription, leading to clinical complete response rate (cCR) 94%, pathological complete response rate (pCR) to 39 percent, although the clinical effectiveness of good, but be careful of this prescription a substantial proportion of white blood cells to reduce the situation.